Intra-Cellular Therapies
ITCI75
$131.87arrow_drop_down0.01%-$0.02
ITCI75
$131.87
arrow_drop_down0.01%| Key Stats | |
|---|---|
| Open | $131.90 |
| Prev. Close | $131.92 |
| EPS | -0.72 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 126.47 | 131.97 |
| 52 Week Range | 45.50 | 131.97 |
| Ratios | |
|---|---|
| EPS | -0.72 |
| Fundamentals | |
|---|---|
| Payout Ratio | - |
| Industry average yield | 2.87% |
| Last Dividend pay date | - |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
ITCI-
US Healthcare Sector-
US Market-
warning
ITCI / Market
ITCI lose to the US Market which returned 1.29% over the last twenty four hours.warning
ITCI / Healthcare Sector
ITCI lose to the US Healthcare sector which returned 3.64% over the last twenty four hours.Intra-Cellular Therapies (ITCI) Statistics
Keep an eye on Intra-Cellular Therapies
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
How has Intra-Cellular Therapies (ITCI) stock's performance compared to its sector and the market over the past year?
Over the past year, Intra-Cellular Therapies (ITCI) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.41%, Intra-Cellular Therapies has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 35.60%, it has fallen short of the market average. This comparison highlights Intra-Cellular Therapies 's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Intra-Cellular Therapies (ITCI) stock?
The PE ratio for Intra-Cellular Therapies (ITCI) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help
What is the EPS of Intra-Cellular Therapies (ITCI) stock?
The Earnings Per Share (EPS) for Intra-Cellular Therapies (ITCI), calculated on a diluted basis, is -$0.72. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of Intra-Cellular Therapies (ITCI) stock?
The operating margin for Intra-Cellular Therapies (ITCI) is -14.66%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Intra-Cellular Therapies (ITCI) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Intra-Cellular Therapies (ITCI) is -$116.21M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Intra-Cellular Therapies (ITCI) have?
Intra-Cellular Therapies (ITCI) has a total debt of $16.98M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$289.97M.